K-1728 / KymaThera - LARVOL DELTA

PIKYMA-01: A Phase 1/2a Study of K-1728 in Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=110 | Not yet recruiting | Sponsor: KymaThera, Inc.

First-in-human • New P1/2 trial • Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • PIK3CA